Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

ClinicalTrials.gov ID: NCT04130516

Public ClinicalTrials.gov record NCT04130516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 7, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

Study identification

NCT ID: NCT04130516
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Linnaeus Therapeutics, Inc.; Industry
Enrollment: 200 participants

Conditions and interventions

Conditions

Solid Tumor, Adult

Interventions

LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER Drug
Pembrolizumab - anti-PD-1 antibody Biological

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 20, 2019
Primary completion: Dec 30, 2026
Completion: Dec 14, 2027
Last update posted: Dec 17, 2025

2019 – 2027

United States locations

U.S. sites: 10
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Cedars-Sinai Medical Center	Los Angeles	California	90048	Recruiting
Yale Cancer Center	New Haven	Connecticut	06519	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
University of New Mexico Comprehensive Cancer Center	Albuquerque	New Mexico	87106	Recruiting
Columbia University Herbert Irving Comprehensive Cancer Center	New York	New York	10032	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19106	Recruiting
Thomas Jefferson University, Sidney Kimmel Cancer Center	Philadelphia	Pennsylvania	19107	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
The START Center for Cancer Care	San Antonio	Texas	78229	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04130516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 17, 2025 · Synced May 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04130516 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →